ProPhase Labs's gross profit for the
three
months ended in Sep. 2024 was $-0.17 Mil. ProPhase Labs's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.13 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. ProPhase Labs's gross profit for the
three
months ended in Sep. 2024 was $-0.17 Mil. ProPhase Labs's Revenue for the
three
months ended in Sep. 2024 was $3.15 Mil. Therefore, ProPhase Labs's Gross Margin % for the quarter that ended in Sep. 2024 was -5.24%.
ProPhase Labs had a gross margin of -5.24% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of ProPhase Labs was 64.25%. The lowest was -32.39%. And the median was 34.73%.
ProPhase Labs Gross Profit Historical Data
The historical data trend for ProPhase Labs's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ProPhase Labs's Gross Profit
For the Diagnostics & Research subindustry, ProPhase Labs's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Gross Profit distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Gross Profit falls into.
ProPhase Labs Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
ProPhase Labs's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.13 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ProPhase Labs (NAS:PRPH) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ProPhase Labs had a gross margin of -5.24% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
ProPhase Labs Gross Profit Related Terms
Thank you for viewing the detailed overview of ProPhase Labs's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRPH has been successfully added to your 